Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 14/20 | 0.48 |
| ▸ | GSK3B | P49841 | 8/20 | 0.48 |
| ▸ | CLK2 | P49760 | 3/20 | 0.48 |
| ▸ | CLK3 | P49761 | 3/20 | 0.48 |
| ▸ | ACHE | P22303 | 3/20 | 0.46 |
| ▸ | WNT1 | P04628 | 3/20 | 0.44 |
| ▸ | OGA | O60502 | 1/20 | 0.42 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.41 |
| ▸ | PSMB9 | P28065 | 1/20 | 0.41 |
| ▸ | MAPK7 | Q13164 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17162236 | 0.90 | ACHE (0.51) | DYRK1AGSK3BCLK2CLK3ACHE | |
| SCHEMBL24035880 | 0.87 | ACHE (0.60) | CLK2ACHEOGAPSMB8PSMB9 | |
| SCHEMBL3766078 | 0.85 | ACHE (0.58) | DYRK1AGSK3BCLK2ACHEWNT1 | |
| SCHEMBL19295835 | 0.85 | OGA (0.56) | DYRK1AGSK3BCLK2CLK3ACHE | |
| SCHEMBL22660198 | 0.85 | GSK3B (0.50) | DYRK1AGSK3BCLK2CLK3ACHE | |
| SCHEMBL1336383 | 0.84 | ACHE (0.49) | DYRK1AGSK3BCLK2CLK3ACHE | |
| SCHEMBL24036427 | 0.83 | ROCK1 (0.46) | ACHEOGAPSMB8PSMB9 | |
| SCHEMBL22411770 | 0.83 | GSK3B (0.47) | DYRK1AGSK3BACHEPSMB8PSMB9 | |
| SCHEMBL26419961 | 0.83 | DYRK1A (0.53) | DYRK1AGSK3BCLK2CLK3ACHE | |
| SCHEMBL24035877 | 0.79 | ROCK1 (0.44) | ACHEOGAPSMB8PSMB9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11807644-B2 | Methods and compounds for restoring mutant p53 function | PMV PHARMACEUTICALS, INC. (US) | 2023-11-07 | — | — | US | disclosed |
| US-11807644-B2 | Methods and compounds for restoring mutant p53 function | PMV PHARMACEUTICALS, INC. (US) | 2023-11-07 | — | — | US | disclosed |
| CN-116710430-A | Methods and compounds for restoring mutant p53 function | 皮姆维制药公司 | 2023-09-05 | — | — | CN | disclosed |
| EP-4149459-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT P53 FUNCTION | PMV Pharmaceuticals, Inc. (US) | 2023-03-22 | — | — | EP | disclosed |
| US-20230002403-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION | PMV PHARMACEUTICALS, INC. | 2023-01-05 | — | — | US | disclosed |
| WO-2021231474-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION | PMV PHARMACEUTICALS, INC. (US) | 2021-11-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230002403-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION | TP53, TP53BP1, HRAS | DYRK1A 3413/4885GSK3B 2210/4885CLK2 1111/4885 |
| US-11807644-B2 | Methods and compounds for restoring mutant p53 function | TP53, TP53BP1, HRAS | DYRK1A 3413/4885GSK3B 2210/4885CLK2 1111/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.